John Strickler, MD

The expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.

Focusing on the BESPOKE CRC study, John H. Strickler, MD, reviews recent updates presented at ASGO GI 2024 and discusses subset analyses from the trial.

An overview of the rationale and study design of the INTERCEPT study in patients with colorectal cancer, with a focus on the early key findings.

Arvind N. Dasari, MD, MS, presents the third patient profile of the discussion, a 62-year-old woman with colon cancer, highlighting the role of MRD testing in guiding treatment decisions in the surveillance setting.

Stacey Cohen, MD, reviews the initial results from the phase 2 COBRA study focused on ctDNA as a predictive biomarker in adjuvant chemotherapy for patients with stage II colon cancer.

Arvind N. Dasari, MD, MS, gives an overview of the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA clinical trial.

Experts on colorectal cancer provide comprehensive insights on the GALAXY study, highlighting key updates that were presented at ASCO GI 2024.

Aparna Parikh, MD, reviews the DYNAMIC trial, which is focused on ctDNA-guided adjuvant therapy in early-stage colorectal cancer.

Stacey Cohen, MD, presents the case of a 39-year-old woman with high-risk stage II colorectal cancer, highlighting how ctDNA helped inform treatment selection.

The expert panel provides a comprehensive overview of the COSMOS-CRC-03 study and touch on the importance of also looking at real-world data.

An overview of prospective trial data surrounding MRD testing in early-stage CRC and the impact of these findings on the overall treatment landscape.

Michael Foote, MD, presents the case of a 50-year-old man with stage III colorectal cancer, highlighting the role of MRD testing in patient monitoring and treatment management.

GI medical oncologists discuss MRD testing practices in colorectal cancer and provide insights on challenges associated with testing.

Arvind N. Dasari, MD, MS, provides clinical insights on MRD testing modalities, highlighting factors that inform the decision on which platform to use in practice.

A panel of medical oncologists introduce themselves and provide an overview of circulating tumor DNA (ctDNA) and how it relates to MRD (minimal residual disease) testing in colorectal cancer (CRC).

An expert from the Duke University School of Medicine describes how the FDA approval of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer will improve access to treatment.

The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.

Elle Charnisky, a patient with HER2+ metastatic colorectal cancer, and Deanne Griffie, a nurse practitioner, share advice for patients and caregivers living with HER2+ mCRC.

Deanna Griffie, MSN, AGNP-BC, and Tanios Bekaii-Saab, MD, explain how they manage the toxicities of tucatinib in patients with HER2+ mCRC, and how they educate patients on what to expect.

John Strickler, MD, details the design and outcomes of the MOUNTAINEER trial investigating the combination treatment of tucatinib with trastuzumab for HER2+ metastatic colorectal cancer.

Deanna Griffie, MSN, AGNP-BC, shares how common toxicities in patients with HER2+ mCRC being treated with trastuzumab deruxtecan are treated at her clinic.

Dr Tanios Bekaii-Saab describes for which patient groups he would use anti-HER2 therapies as a second-line treatment for HER2+ metastatic colorectal cancer.

Patient Elle Charnisky shares her experience with a conventional chemotherapy treatment for her HER2+ metastatic colorectal cancer before transitioning to targeted therapies.

Dr Bekaii-Saab provides an overview of the first-line treatment options in metastatic colorectal cancer, and the factors that impact treatment decision-making.

Tanios Bekaii-Saab, MD, explains the barriers to molecular testing for patients with metastatic colorectal cancer, and how they can be addressed.

Elle Charnisky describes her experience with molecular testing, and Nurse Practitioner Deanna Griffie details how she explains testing to patients with metastatic colorectal cancer.

Dr Tanios Bekaii-Saab explains the rarity of HER2+ metastatic colorectal cancer and how his clinical practice detects HER2 alterations.

Patient Elle Charnisky shares the symptoms that led to her diagnosis of HER2+ metastatic colorectal cancer, and the online resources she used for education after.

Tanios Bekaii-Saab, MD, provides a brief overview of the typical presentation and diagnosis of metastatic colorectal cancer.

Expert oncologists look toward future utilization of circulating tumor DNA testing and consider how the field of oncology may evolve.